ICD-10-CM 2027 diagnosis code
C81.17Nodular sclerosis Hodgkin lymphoma, spleen
C81.17 is a valid, billable ICD-10-CM code for nodular sclerosis hodgkin lymphoma, spleen. It can be reported on claims for dates of service from October 1, 2026 – September 30, 2027.
Code last changed in FY2017 (effective October 1, 2016). Source: official FY2027 ICD-10-CM release from CDC/NCHS and CMS. Page updated September 29, 2026. About our data
About C81.17
C81.17 is the ICD-10-CM diagnosis code for nodular sclerosis Hodgkin lymphoma, spleen. It belongs to category C81 (Hodgkin lymphoma), block C81-C96 (malignant neoplasms of lymphoid, hematopoietic and related tissue) and chapter 2 (neoplasms). It is billable, so it can be reported on its own for dates of service from October 1, 2026 through September 30, 2027.
Within C81.1 (nodular sclerosis Hodgkin lymphoma), C81.17 is specifically for nodular sclerosis Hodgkin lymphoma, spleen. Related codes cover unspecified site (C81.10), lymph nodes of head, face, and neck (C81.11), intrathoracic lymph nodes (C81.12), intra-abdominal lymph nodes (C81.13), lymph nodes of axilla and upper limb (C81.14), lymph nodes of inguinal region and lower limb (C81.15), intrapelvic lymph nodes (C81.16), lymph nodes of multiple sites (C81.18) and 2 more.
As a secondary diagnosis it is a CC (complication or comorbidity), which can move an inpatient stay into the "with CC" MS-DRG of its family, unless the principal diagnosis excludes it.
In MS-DRG v44.0, it is part of the grouping logic for DRG 820 (Lymphoma and Leukemia with Major O.R. Procedures with MCC, relative weight 6.2481), DRG 821 (Lymphoma and Leukemia with Major O.R. Procedures with CC, relative weight 2.2023), DRG 822 (Lymphoma and Leukemia with Major O.R. Procedures without CC/MCC, relative weight 1.1272), DRG 823 (Lymphoma and Non-Acute Leukemia with Other Procedures with MCC, relative weight 4.6059), DRG 824 (Lymphoma and Non-Acute Leukemia with Other Procedures with CC, relative weight 2.2515), DRG 825 (Lymphoma and Non-Acute Leukemia with Other Procedures without CC/MCC, relative weight 1.2995) and 3 more, in MDC 17 (Myeloproliferative Diseases and Disorders, Poorly Differentiated Neoplasms), as a principal or secondary diagnosis. The DRG a claim lands in depends on the principal diagnosis, procedures and any CC/MCC secondary diagnoses.
It has been part of ICD-10-CM since the code set took effect on October 1, 2015, and changed in FY2017 (title revised).
Before ICD-10, this condition was coded in ICD-9-CM as 201.57 (hodgkin's disease, nodular sclerosis, spleen).
Notes that apply from higher levels
Instructions written at a parent level also apply to C81.17.
› From C81 Hodgkin lymphoma
- personal history of Hodgkin lymphoma (Z85.71)
Broader instructions also apply from C81-C96 Malignant neoplasms of lymphoid, hematopoietic and related tissue and Chapter 2: Neoplasms.
MS-DRG v44.0 grouping
All DRGs →Inpatient MS-DRGs this diagnosis can group to, as the principal or a secondary diagnosis, depending on the rest of the claim.
MDC 17 · Myeloproliferative Diseases and Disorders, Poorly Differentiated Neoplasms
MDC 17 · Myeloproliferative Diseases and Disorders, Poorly Differentiated Neoplasms
MDC 17 · Myeloproliferative Diseases and Disorders, Poorly Differentiated Neoplasms
ICD-9-CM equivalent
Converter →- 201.57Hodgkin's disease, nodular sclerosis, spleenexact
From the CMS 2018 General Equivalence Mappings (GEMs), the final GEMs release.
Code history
- 2016
- 2017
- 2018
- 2019
- 2020
- 2021
- 2022
- 2023
- 2024
- 2025
- 2026
- 2027
- FY2016 (effective 10/1/2015): Added (first year of ICD-10-CM)
- FY2017 (effective 10/1/2016): Title revised — was “Nodular sclerosis classical Hodgkin lymphoma, spleen”
Common questions about C81.17
Is C81.17 billable?
- Yes. C81.17 is a billable/specific ICD-10-CM code valid for FY2027 (October 1, 2026 – September 30, 2027).
Can C81.17 be used as a principal diagnosis?
- Yes. The Medicare Code Editor doesn't restrict C81.17 as a principal diagnosis.
Is C81.17 a CC or MCC?
- C81.17 is a CC (complication or comorbidity) under MS-DRG v44.0, unless excluded by the principal diagnosis.
What DRG does C81.17 group to?
- C81.17 is used in the MS-DRG v44.0 logic for MS-DRG 820 (Lymphoma and Leukemia with Major O.R. Procedures with MCC), MS-DRG 821 (Lymphoma and Leukemia with Major O.R. Procedures with CC), MS-DRG 822 (Lymphoma and Leukemia with Major O.R. Procedures without CC/MCC), MS-DRG 823 (Lymphoma and Non-Acute Leukemia with Other Procedures with MCC), MS-DRG 824 (Lymphoma and Non-Acute Leukemia with Other Procedures with CC), MS-DRG 825 (Lymphoma and Non-Acute Leukemia with Other Procedures without CC/MCC) and 3 more. Which one applies depends on whether it is the principal diagnosis and on the rest of the claim.
What is the ICD-9 code for C81.17?
- The CMS General Equivalence Mappings map C81.17 to ICD-9-CM 201.57.